# Auto Review: results.txt

Generated: 2026-04-28 15:18
Reviewer: Qwen2.5-32B-Instruct-AWQ (auto_review.py)

## Summary

- **Samples**: 8
- **Clean**: 0/8
- **P0** (hallucination): 0
- **P1** (major error): 4
- **P2** (minor issue): 20

### Critical Issues

- **ROW 15** [P1]: Wrong voice and incomplete information.
- **ROW 36** [P1]: Incomplete sentence with missing critical information.
- **ROW 40** [P1]: Incomplete sentence with missing critical information.
- **ROW 82** [P1]: Incomplete sentence with missing critical info (missing 'FOLFOXIRI').

---

## ROW 1 — ⚠️ ISSUES

**Type**: Moderately differentiated pancreatic adenocarcinoma
**Stage**: 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Stage_of_Cancer | Stage of cancer is left blank, though it can be reasonably inferred as potentially resectable based on the note. | potentially resectable pancreatic adenocarcinoma |
| P2 | Lab_Results.lab_summary | CA 19-9 value is incorrect (6,105 instead of 77,736 at baseline and 6,105 after treatment). | Baseline *****-9 markedly elevated at 77,736 (in the context of obstructive jaundice)...recently ima |
| P2 | Current_Medications.current_meds | Field is empty, but the note mentions ongoing chemotherapy treatment. | He is now s/p 4 cycles of neoadjuvant chemotherapy with [REDACTED] |

*Extraction summary*: Most fields are clean, but there are minor issues with the stage of cancer, lab results, and current medications.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 4 — ⚠️ ISSUES

**Type**: Metastatic pancreatic ductal adenocarcinoma
**Stage**: Stage IV (metastatic to liver and peritoneum)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medication (gemcitabine-based regimen mentioned as a potential future treatment, but not listed under current medications). | We talked about potential side fx and risks, esp in terms of infectious complications, and adverse i |
| P2 | Treatment_Changes | Supportive medications listed are not exclusively cancer-related supportive care. | Supportive medications listed include Fentanyl patch, Dilaudid, DexAMETHasone, ondansetron, which ar |

*Extraction summary*: Most fields are clean, but there are minor issues with missing cancer-related medication and non-exclusive listing of supportive medications.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 15 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: Originally Stage IV, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | current_meds | The patient is taking turmeric, mushroom extract, and cannabis products, which are not included in the current_meds field. | He does take turmeric, mushroom extract and cannabis products |
| P2 | Treatment_Changes | The note mentions exploring clinical trial options, particularly cell therapy, which is not reflected in the Treatment_Changes field. | As he was very interested in clinical trials, we decided to explore this with the phase I group as w |
| P2 | Imaging_Plan | The note indicates a recent CT scan was performed, but the Imaging_Plan field only mentions future CT Chest without specifying the purpose or timing. | A recent CT scan done shows new peritoneal metastases. |

*Extraction summary*: Most fields are clean, but there are minor issues with missing complementary therapies, clinical trial exploration, and recent imaging details.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Wrong voice and incomplete information. | We will resume a medication. He responded initially quite well to a medication b |

*Letter summary*: Letter has issues with voice and incomplete information.

---

## ROW 36 — ⚠️ ISSUES

**Type**: Nonfunctioning pancreatic neuroendocrine tumor
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Incomplete. Everolimus is listed, but the note mentions multiple doses (2.5 mg and 10 mg). | everolimus (AFINITOR) 2.5 mg TAB 7.5 mg (3 tabs) daily  90 tablet  6    everolimus 10 mg TAB Take 1 |
| P2 | Treatment_Changes | Incomplete. The note mentions holding everolimus during partial SBO, but this detail is not fully captured. | Everolimus held during that period of time, resumed two weeks ago. |
| P2 | Treatment_Goals | Slightly imprecise. 'Palliative' is correct, but 'durable disease control' is also mentioned in the note. | with evidence of good durable disease control and reasonably good (in fact, improved) tolerance on c |
| P2 | Medication_Plan | Slightly imprecise. The note mentions starting non-insulin pharmacologic treatment in the future, but this is not clearly stated. | discussed potential plan to start non-insulin pharmacologic rx in the future. |

*Extraction summary*: Most fields are clean, but there are minor issues related to completeness and precision in medication details and treatment goals.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical information. | Your dose of everolimus was reduced . |

*Letter summary*: Letter contains an incomplete sentence with missing critical information.

---

## ROW 40 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medications (gemcitabine and Abraxane) in the medication plan. | We recommend a course of treatment with gemcitabine and Abraxane. |

*Extraction summary*: One minor issue identified regarding the inclusion of cancer-related medications in the medication plan.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical information. | We plan to increase the dose of your fentanyl patch to and added Reglan and when |

*Letter summary*: Letter contains an incomplete sentence with missing critical information.

---

## ROW 43 — ⚠️ ISSUES

**Type**: Pancreatic adenocarcinoma
**Stage**: Borderline resectable pancreatic adenocarcinoma due to <180 degrees of vascular 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing cancer-related medications. | The note mentions 'Continue to monitor [REDACTED] July 04 [REDACTED] 4 weeks.' and 'Continue [REDACT |

*Extraction summary*: Most fields are clean, but the current medications related to cancer treatment are missing.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 59 — ⚠️ ISSUES

**Type**: Well to moderately differentiated adenocarcinoma of the pancreas
**Stage**: 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The field is empty, but the note provides enough information to infer a stage. | Pathology showed a 2.5 cm well to moderately differentiated adenocarcinoma with a positive retroperi |
| P2 | Cancer_Diagnosis.Type_of_Cancer | The type of cancer is described as 'Well to moderately differentiated adenocarcinoma of the pancreas', but the note specifies 'pylorus sparing gastrectomy' which might imply a different location. | Pathology showed a 2.5 cm well to moderately differentiated adenocarcinoma with a positive retroperi |
| P2 | Current_Medications.current_meds | The field is empty, but the note mentions 'metFORMIN' which is related to hyperglycemia consistent with type 2 diabetes, though not directly cancer-related. | METFORMIN 500 mg 24 hour extended release tablet Take 500 mg by mouth daily with dinner |
| P2 | Treatment_Changes.recent_changes | The field is empty, but the note indicates ongoing surveillance and no recent changes in treatment. | She will continue on surveillance. We'll see her again in 6 months. |
| P2 | Imaging_Plan.imaging_plan | The field only mentions 'CT Chest', but the note suggests ongoing surveillance which likely includes both CT Chest and CT Abdomen/Pelvis. | Comprehensive metabolic panel and complete blood count results are provided, and imaging reports for |

*Extraction summary*: Most fields are clean, but there are minor issues with missing inferred cancer stage, potential misclassification of cancer type, and incomplete imaging plan.

### Letter: ✅ Clean

*Letter summary*: Letter is clean.

---

## ROW 82 — ⚠️ ISSUES

**Type**: Pancreatic adenocarcinoma
**Stage**: Stage IV (metastatic to liver and lung)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Current_Medications | Missing current cancer-related medication (fentanyl patch). | fentaNYL (DURAGESIC) 25 mcg/hr patch Place 1 patch onto the skin every other day. For cancer pain. |

*Extraction summary*: One minor issue found in Current_Medications.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete sentence with missing critical info (missing 'FOLFOXIRI'). | We started a new treatment called modified a chemotherapy regimenIRI, which incl |

*Letter summary*: Letter contains an incomplete sentence with missing critical info.

---

